Sign Up
OverviewAPI
Mesoblast Limited engages in constructive dialogue with the FDA on its cellular medicine products for pediatric acute graft versus host disease and chronic heart failure patients. The company aims to resubmit a key Biologics License Application and seeks accelerated approval for treating end-stage heart failure.

Ask a question